Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 40
Filter
2.
Saúde Soc ; 31(1): e210116, 2022.
Article in Portuguese | LILACS | ID: biblio-1352216

ABSTRACT

Resumo Este artigo analisa a percepção de homens usuários de testosterona acerca dos efeitos adversos no uso do hormônio, a fim de refletir sobre a eficácia e o alcance de ações em saúde voltadas para essa prática. Os dados empíricos foram obtidos a partir de 21 relatos de história de vida de homens que utilizam a testosterona, com ou sem acompanhamento médico, de perfil variado, coletados em 2016 majoritariamente no Rio de Janeiro. A discussão se apoia nos estudos de gênero e de masculinidades para argumentar como os homens interpretam os impactos do uso da testosterona a partir de uma valorização de características masculinas associadas a um ideal normalizador de masculinidade. Os resultados apontam uma percepção generalizada no campo de que o hormônio causa pouco ou nenhum mal, através de um processo de invisibilização ou ressignificação dos efeitos potencialmente negativos. Além disso, há um movimento de deslocamento dos problemas associados ao uso a personagens estereotipadas, num processo de desresponsabilização de si e reafirmação de atributos de um ideal de masculinidade. Com isso, busca-se contribuir para a construção de ações em saúde mais adequadas ao cotidiano dos usuários e, portanto, mais eficazes.


Abstract This article analyzes the perception of male users of testosterone about the adverse effects of the hormone, aiming to challenge the effectiveness and scope of health actions for this practice. Empirical data were obtained in 2016, mostly in Rio de Janeiro, from life history interviews with 21 male users of testosterone, with or without medical monitoring, from different backgrounds. In the light of gender and masculinity studies, it discusses how men interpret the impacts of testosterone use from a social valuation of certain traits associated with a normalizing manhood ideal. Results indicate an invisibilization or re-signification of potentially negative effects of the hormone, culminating in a widespread perception that it causes little or no harm. The problems associated with testosterone use acquire stereotyped characters, through a process of denying self-responsibility and reaffirming attributes of an ideal type of masculinity. This study is expected to contribute to the development of more adequate and thus more effective health actions to users' daily lives.


Subject(s)
Humans , Male , Gonadal Steroid Hormones , Testosterone/adverse effects , Masculinity
4.
Rev. Hosp. Ital. B. Aires (2004) ; 40(1): 34-38, mar. 2020. tab
Article in Spanish | LILACS | ID: biblio-1102292

ABSTRACT

Las mujeres han sido tratadas por décadas con testosterona intentando aliviar una gran variedad de síntomas con riesgos y beneficios inciertos. En la mayoría de los países, la testosterona se prescribe "off-label", de modo que las mujeres están utilizando compuestos y dosis ideadas para tratamientos en hombres. En este sentido, varias sociedades médicas de distintos continentes adoptaron recientemente por consenso una toma de posición sobre los beneficios y potenciales riesgos de la terapia con testosterona en la mujer, explorar las áreas de incertidumbre e identificar prácticas de prescripción con potencial de causar daño. Las recomendaciones con respecto a los beneficios y riesgos de la terapia con testosterona se basan en los resultados de ensayos clínicos controlados con placebo de al menos 12 semanas de duración. A continuación se comentan las recomendaciones. (AU)


There are currently no clear established indications for testosterone replacement therapy for women. Nonetheless, clinicians have been treating women with testosterone to alleviate a variety of symptoms for decades with uncertainty regarding its benefits and risks. In most countries, testosterone therapy is prescribed off-label, which means that women are using testosterone formulations or compounds approved for men with a modified dose for women. Due to these issues, there was a need for a global Consensus Position Statement on testosterone therapy for women based on the available evidence from placebo randomized controlled trials (RCTs). This Position Statement was developed to inform health care professionals about the benefits and potential risks of testosterone therapy intended for women. The aim of the Consensus was to provide clear guidance as to which women might benefit from testosterone therapy; to identify symptoms, signs, and certain conditions for which the evidence does not support the prescription of testosterone; to explore areas of uncertainty, and to identify any prescribing practices that have the potential to cause harm. (AU)


Subject(s)
Humans , Female , Aged , Testosterone/therapeutic use , Postmenopause/drug effects , Appetite Depressants/adverse effects , Phenytoin/adverse effects , Placebos/administration & dosage , Psychotropic Drugs/adverse effects , Tamoxifen/adverse effects , Testosterone/administration & dosage , Testosterone/analysis , Testosterone/adverse effects , Testosterone/pharmacology , Cardiovascular Agents/adverse effects , Indomethacin/adverse effects , Gonadotropin-Releasing Hormone/adverse effects , Postmenopause/physiology , Controlled Clinical Trials as Topic , Cholinergic Antagonists/adverse effects , Contraceptives, Oral/adverse effects , Sexual Dysfunctions, Psychological/etiology , Sexual Dysfunctions, Psychological/therapy , Danazol/adverse effects , Consensus , Aromatase Inhibitors/adverse effects , Off-Label Use , Factor Xa Inhibitors/adverse effects , Amphetamines/adverse effects , Histamine Antagonists/adverse effects , Androgen Antagonists/adverse effects , Androgens/physiology , Ketoconazole/adverse effects , Narcotics/adverse effects
6.
Rev. cuba. endocrinol ; 30(3): e213, sept.-dic. 2019. tab, graf
Article in Spanish | LILACS, CUMED | ID: biblio-1126443

ABSTRACT

RESUMEN Introducción: El hipogonadismo masculino puede provocar una reducción importante de la calidad de vida. La determinación de testosterona total constituye la opción inicial para el diagnóstico bioquímico del hipogonadismo. Objetivo: Determinar el intervalo de referencia de testosterona total para la población masculina en edad reproductiva del municipio Plaza de la Revolución. Métodos: Se realizó un estudio transversal y descriptivo, en una muestra representativa (n= 143) de la población masculina entre 20 y 40 años de edad, del municipio Plaza de la Revolución. Para el reclutamiento de la muestra se utilizó un método directo. El intervalo de referencia se estableció mediante un método no paramétrico. Se realizó interrogatorio, examen físico, complementarios bioquímicos (glucemia, colesterol, triglicéridos, HDL-c, LDL-c), y hormonales (testosterona total, PRL, FSH y LH). Resultados: El promedio de edad fue de 29,7 años. El índice de masa corporal osciló entre 18,95 y 29,88 kg/m2 (valor medio 24,15). Las medias de las circunferencias de cintura y cadera fueron de 86,62 cm y 99,77 cm respectivamente. El intervalo de referencia de testosterona total calculado para la población masculina del municipio Plaza de la Revolución, fue de 7,69 a 40,52 nmol/L. La mediana para la testosterona total fue de 19,10 nmol/L. Conclusiones: El intervalo de referencia de testosterona total calculado para la población masculina adulta (20 - 40 años) del municipio Plaza de la Revolución difiere del reportado por el fabricante del kit diagnóstico y puede resultar de utilidad en la práctica clínica(AU)


ABSTRACT Introduction: Male hypogonadism may cause a significant reduction in the quality of life. The determination of total testosterone constitutes the initial option for the biochemical diagnosis of hypogonadism. Objective: To determine the reference interval of total testosterone for the male population in reproductive age of Plaza de la Revolución municipality. Methods: It was conducted a cross-sectional and descriptive study in a representative sample (n=143) of the male population from 20 to 40 years old of Plaza de la Revolución municipality. For the recruitment of the sample it was used a direct method. The reference interval was established through a non-parametric method. There were conducted interrogations, physical examination, complementary biochemical (blood glucose, cholesterol, triglycerides, HDL-c, LDL-c), and hormonal tests (total testosterone, PRL, FSH and LH). Results: The average age was 29.7 years. The body mass index ranged between 18.95 and 29.88 kg/m2 (mean value of 24.15). The means of the waist and hip circumferences were 86.62 and 99.77 cm, respectively. The reference interval of total testosterone calculated for the male population of Plaza de la Revolución municipality was of 7.69 to 40.52 nmol/L. The mean for total testosterone was 19.10 nmol/L. Conclusions: The reference interval of total testosterone calculated for the adult male population (20 - 40 years old) of Plaza de la Revolución municipality differs from that reported by the manufacturer of the diagnostic kit and it can be useful in clinical practice(AU)


Subject(s)
Humans , Male , Adult , Physical Examination/methods , Testosterone/adverse effects , Hypogonadism/diagnosis , Quality of Life , Reference Values , Body Mass Index , Epidemiology, Descriptive , Cross-Sectional Studies
7.
Arch. endocrinol. metab. (Online) ; 63(3): 190-198, May-June 2019. tab
Article in English | LILACS | ID: biblio-1011166

ABSTRACT

ABSTRACT Objective To summarize current evidence regarding testosterone treatment for women with low sexual desire. Materials and methods The Female Endocrinology and Andrology Department of the Brazilian Society of Endocrinology and Metabolism invited nine experts to review the physiology of testosterone secretion and the use, misuse, and side effects of exogenous testosterone therapy in women, based on the available literature and guidelines and statements from international societies. Results Low sexual desire is a common complaint in clinical practice, especially in postmenopausal women, and may negatively interfere with quality of life. Testosterone seems to exert a positive effect on sexual desire in women with sexual dysfunction, despite a small magnitude of effect, a lack of long-term safety data, and insufficient evidence to make a broad recommendation for testosterone therapy. Furthermore, there are currently no testosterone formulations approved for women by the relevant regulatory agencies in the United States, Brazil, and most other countries, and testosterone formulations approved for men are not recommended for use by women. Conclusion Therefore, testosterone therapy might be considered if other strategies fail, but the risks and benefits must be discussed with the patient before prescription. Arch Endocrinol Metab. 2019;63(3):190-8


Subject(s)
Humans , Female , Adolescent , Adult , Middle Aged , Aged , Young Adult , Sexual Dysfunction, Physiological/drug therapy , Testosterone/therapeutic use , Androgens/therapeutic use , Libido/drug effects , Societies, Medical , Testosterone/adverse effects , Testosterone/blood , Practice Guidelines as Topic , Androgens/adverse effects , Androgens/blood
9.
Evid. actual. práct. ambul ; 21(3): 89-91, oct. 2018. tab., ilus.
Article in Spanish | LILACS | ID: biblio-1016246

ABSTRACT

El acné es la enfermedad dermatológica más común de la adolescencia. Aunque casi todos los casos remiten alrededor de la tercera década de la vida, cuando este problema conlleva una carga emocional para el paciente se requiere indicar tratamiento. En esta actualización, los autores revisan los distintos grados de compromiso de esta patología, el tratami-ento y los niveles de evidencia que tiene cada uno de ellos, con el objetivo de facilitar a los médicos de atención primaria el manejo de los pacientes que presentan esta enfermedad. (AU)


Acne is the most common dermatological condition in adolescents. Even though almost all cases will resolve around the third decade of life, treatment is indicated when this health problem carries an emotional burden for the patient. In this update, the authors review the grades of involvement of the disease and the available treatments according to levels of evidence, with the aim of helping primary care physicians to manage the patients presenting this illness. (AU)


Subject(s)
Humans , Male , Female , Adolescent , Adult , Young Adult , Acne Vulgaris/therapy , Acne Conglobata/therapy , Anxiety , Self Concept , Skin Diseases/etiology , Testosterone/adverse effects , Cicatrix/prevention & control , Skin Diseases, Papulosquamous/therapy , Dermatitis, Seborrheic/diagnosis , Acne Vulgaris/diagnosis , Acne Vulgaris/pathology , Acne Vulgaris/psychology , Acne Vulgaris/drug therapy , Rosacea/diagnosis , Acne Conglobata/diagnosis , Folliculitis/diagnosis
10.
Braz. j. med. biol. res ; 51(1): e6388, 2018. graf
Article in English | LILACS | ID: biblio-889014

ABSTRACT

The abuse of psychoactive drugs is considered a global health problem. During the last years, a relevant number of studies have investigated the relationship between anabolic-androgenic steroids (AAS) and other psychoactive drugs. AAS, such as testosterone, can cause a dependence syndrome that shares many features with the classical dependence to psychoactive substances. Pre-clinical evidence shows that there are interactions between testosterone and psychoactive drugs, such as cocaine. However, few studies have been performed to investigate the effect of repeated testosterone treatment on behavioral effects of amphetamine derivatives, such as fenproporex. The purpose of the present study was to investigate the effects of repeated testosterone administration on fenproporex-induced locomotor activity in adolescent and adult rats. Adolescent male Wistar rats were injected with testosterone (10 mg/kg sc for 10 days). After 3 days, animals received an acute injection of fenproporex (3.0 mg/kg ip) and the locomotor activity was recorded during 40 min. Thirty days later, the same animals received the same treatment with testosterone followed by a fenproporex challenge injection as described above. Our results demonstrated that repeated testosterone induced behavioral sensitization to fenproporex in adolescent but not in adult rats. These findings suggest that repeated AAS treatment might increase the dependence vulnerability to amphetamine and its derivatives in adolescent rats.


Subject(s)
Animals , Male , Amphetamines/pharmacology , Anabolic Agents/pharmacology , Androgens/pharmacology , Locomotion/drug effects , Testosterone/adverse effects , Time Factors , Behavior, Animal/drug effects , Age Factors , Rats, Wistar , Drug Interactions , Amphetamines/adverse effects , Anabolic Agents/adverse effects , Androgens/adverse effects , Injections, Subcutaneous
13.
Rev. cuba. endocrinol ; 27(1): 0-0, ene.-abr. 2016. tab
Article in Spanish | LILACS | ID: lil-780723

ABSTRACT

Introducción: el deseo sexual cambia con el envejecimiento, la verdadera magnitud de estos cambios y los factores que los condicionan son aún objeto de debate. Objetivo: describir las características del deseo sexual en varones adultos mayores del municipio Plaza de la Revolución y su asociación con la testosterona sérica y otras variables. Métodos: estudio transversal descriptivo, con base poblacional. Participaron 510 varones de 60 años y más, sin limitaciones físicas o cognitivas, ni condiciones que causan hipogonadismo, seleccionados mediante muestreo estratificado polietápico complejo entre los residentes del municipio Plaza de la Revolución, en La Habana. Contestaron cuestionario anónimo autoadministrado, se recogieron datos del interrogatorio y examen físico, y se determinó testosterona sérica total. Se evaluaron aspectos del deseo sexual y factores con posible influencia sobre este; se analizaron estadísticas descriptivas y pruebas de chi cuadrado, Kruskal Wallis y regresión logística múltiple. Se cuidaron aspectos éticos. Resultados: la edad de los participantes fue entre 60 y 93 años (mediana 70). El 82,41 por ciento refirió cambios en su deseo sexual en relación con edades previas; de estos, 79,16 por ciento señaló disminución, 11,66 por ciento pérdida y 9,18 por ciento aumento. El 55,02 por ciento dijo tener nivel de deseo sexual medio, 44,53 por ciento lo experimentaban a menudo, y 4,25 por ciento nunca. El 71,22 por ciento refirió estar satisfechos o medianamente satisfechos con su deseo sexual. No se observó relación entre la testosterona sérica y los cambios en el deseo sexual, nivel o frecuencia actual (p> 0,05). La disminución del deseo sexual mostró asociación positiva significativa con la edad mayor a 80 años, disminución de la sensación de bienestar y consumo de medicamentos; y asociación negativa, con la actitud hacia la sexualidad (p< 0,05). La escolaridad, la ocupación, las creencias religiosas, el estado civil, el tiempo de relación de pareja, las enfermedades cónicas, los hábitos tóxicos, los ejercicios físicos, la socialización, el estado psicológico, la educación sexual, la importancia que le conceden a la sexualidad, o tener privacidad, no se relacionaron significativamente con la disminución del deseo sexual. Conclusiones: el deseo sexual cambia con la edad, predominantemente en sentido de disminución, pero la mayoría de los sujetos se sienten satisfechos o medianamente satisfechos, lo experimentan a menudo y en un nivel medio. La disminución del deseo sexual en los sujetos estudiados no depende de la testosterona sérica, y sí de otros factores biológicos, psicológicos y sociales(AU)


Introduction: sexual desire decreases with aging but the real scope of these changes and the factors unleashing them are still a topic under debate. Objective: to describe the characteristics of the sexual desire in older men from Plaza de la Revolution municipality and their association with serum testosterone and other variables. Methods: population-based descriptive and cross-sectional study which involved 510 men aged 60 years and older, who did not present either physical/cognitive handicaps or conditions leading to hipogonadism. They had been selected from the residents of Plaza de la Revolucion municipality in Havana through a complex multistage stratified sampling. They answered a self-administered anonymous questionnaire; their questioning and physical exam data were then collected and the total serum testosterone was determined. Several sexual desire aspects together with the possible influential factors were evaluated; the summary statistics in addition to Chi-square, Kruskall-Wallis's and multiple logistic regression tests were all analyzed. Moreover, ethical aspects were respected. Results: the age of the participants ranged 60 to 93 years (median of 70). In this group, 82.41 percent pointed out that their sexual desire had changed in comparison with earlier ages and from this percentage, 79.16 percent said their desire decreased, 11.66 percent stated it had disappeared whereas in 9.18 percent it had increased. The answers showed that the degree of sexual desire was medium in 55.02 percent of participants, 44.53 percent often felt it whereas 4.25 percent never had it. In the study group, 71.22 percent were satisfied or fairly satisfied with their degree of sexual desire. There was no association between the serum testosterone and the changes in the current degree and frequency of sexual desire (p> 0.05). The decrease in sexual desire showed significant positive association with the age older than 80 years, less sensation of wellbeing and lower consumption of drugs; however, it was negatively associated to the attitude towards sexuality (p< 0.05). Schooling, occupation, religious beliefs, marital status, length of time of a couple relationship, chronic diseases, toxic habits, physical exercising, socialization, psychological condition, sexual education, importance attached to sexuality or to privacy were not significantly associated with decrease of sexual desire. Conclusions: sexual desire changes with the age, particularly towards decrease, but the majority of older men are satisfied or fairly satisfied with it; they often feel it with medium degree. The decreased sexual desire in the studied subjects does not depend on the serum testosterone but it does on other biological, psychological and social factors(AU)


Subject(s)
Humans , Male , Aged , Aged, 80 and over , Hypogonadism/epidemiology , Sex Factors , Sexual Development , Sexuality/statistics & numerical data , Testosterone/adverse effects , Cross-Sectional Studies , Epidemiology, Descriptive
15.
Pesqui. vet. bras ; 30(10): 887-890, out. 2010. ilus, graf, tab
Article in English | LILACS | ID: lil-567932

ABSTRACT

The aim of the present experiment was to investigate the effect of corticosteroids (exogen) on in vitro testosterone secretion after stress by transportation (40 minutes). Feline testes (Felis silvestris catus) were incubated in the following media: TCM 199; TCM 199 + hCG 10_7M; TCM 199 + hydrocortisone 10_7M, or TCM 199 + hCG + hydrocortisone. The animals (n=21) were allocated into three groups: (S) that arrived at 3 h prior to surgery, (A) that remained in the laboratory for 36 h before being submitted to surgical procedure, and (C) that were also allowed to remain for 36 hours in the laboratory before the surgical procedure, but whose testes had been incubated with hydrocortisone prior to incubation in the referred media. The results showed that group S secreted higher levels of testosterone, regardless of the culture media. It is noteworthy that the suppressing action of hydrocortisone sodium succinate led to a reduction in the testosterone concentration, despite the presence of hCG.


O objetivo deste trabalho foi investigar o efeito da hidrocortisona sobre a secreção de testosterona após cultivo in vitro dos testículos, em distintas situações de estresse (transporte) de gatos domésticos (Felis silvestris catus). Testículos foram incubados nos seguintes meios de cultura: TCM 199; TCM 199 + hCG 10_7M; TCM 199 + hydrocortisona 10_7M e TCM 199 + hCG + hidrocortisona. Os animais (n=21) foram alocados em 3 sub-grupos: (S) animal admitido 3 horas antes da orquiectomia, (A) animais orquiectomizados após 36 horas de permanência no biotério e (C) animais que permaneceram por 36 horas no biotério antes da cirurgia e que tiveram seus testículos pré-incubados em hidrocortisona. Os resultados demonstraram que o grupo S secretou maiores valores de testosterona em todas as condições estudadas. É válido mencionar que a supressão promovida pela hidrocortisona também promoveu redução na concentração de testosterona no meio TCM 199, a despeito da presença de hCG.


Subject(s)
Animals , Chorionic Gonadotropin/analysis , Hydrocortisone/administration & dosage , Hydrocortisone/adverse effects , Orchiectomy/methods , Orchiectomy/veterinary , Testosterone/analysis , Testosterone/adverse effects
16.
Rev. cuba. farm ; 44(2)abr.-jun. 2010. tab
Article in Spanish | LILACS | ID: lil-575710

ABSTRACT

La hiperplasia prostàtica benigna, enfermedad común en hombres mayores de 50 años de edad, se caracteriza por el crecimiento incontrolado de la glàndula prostàtica y la presencia de síntomas del tracto bajo urinario. El estrés oxidativo ha sido recientemente asociado con la causa de esta enfermedad. El D-004, extracto lipídico del fruto de la Roystonea regia, ha mostrado reducir la hiperplasia prostàtica inducida por testosterona en roedores y producir efectos antioxidantes in vitro e in vivo, pero sus efectos sobre las enzimas del sistema antioxidante endógeno no han sido estudiados. Este trabajo investigó los efectos del tratamiento oral con D-004, durante 14 días, sobre las enzimas superóxido dismutasa y catalasa en ratas con hiperplasia prostàtica inducida por testosterona. Los animales se distribuyeron en 4 grupos: un control negativo y tres inyectados con testosterona: uno tratado con el vehículo (control positivo) y dos con D-004 (400 y 800 mg/kg, respectivamente). Se determinó la capacidad antioxidante total del plasma y las actividades de las enzimas superóxido dismutasa y catalasa en eritocitos lisados y plasma, respectivamente. El tratamiento oral con D-004 (400 y 800 mg/kg) previno de modo marcado y significativo el agrandamiento de la próstata inducido con testosterona en ratas, y aumentó significativamente la capacidad antioxidante del plasma y la actividad de la catalasa, sin modificar la actividad de la superóxido dismutasa. Estos resultados sugieren que la actividad antioxidante del D-004 està relacionada, al menos parcialmente, con la estimulación de algunas enzimas del sistema antioxidante endógeno.


Benign prostatic hyperplasia, a common disease in men aged over 50 is characterized by uncontrolled growth of prostatic gland and the presence of low urinary tract symptoms. The oxidative stress has been recently associated with the disease cause. The D-004, a lipid extract from Roystonea regia, reduces the prostatic hyperplasia induced by testosterone in rodents and to produce in vitro and in vivo antioxidant effects nut its effects on endogenous antioxidant4e system enzymes haven't been studied. Present paper researched the effects of D-004 oral treatment over 14 days on dismutase and catalase superoxide enzymes in rats with prostatic hyperplasia induced by testosterone. Animals were randomized distributed into 4 groups: a negative control ant three-testosterone injected: one treated with the vehicle (positive control) and two with D-004 (400 and 800 mg/kg, respectively). The plasma total antioxidant ability was determined as well as the activity of catalase and dismutase superoxide enzymes in lysed erythrocyte and plasma, respectively. D-004 (400 and 800 mg/kg) oral treatment markedly and significantly prevented the prostate enlargement induced with testosterone in rats and increased very much the plasma antioxidant activity and of catalase, without modify the superoxide dismutase. These results suggest that D-004 antioxidant activity is partially related to stimulation of some enzymes of the endogenous antioxidant system.


Subject(s)
Rats , Antioxidants , Prostatic Hyperplasia/chemically induced , Testosterone/adverse effects
17.
Arq. bras. endocrinol. metab ; 53(8): 956-962, nov. 2009.
Article in Portuguese | LILACS | ID: lil-537031

ABSTRACT

O hipogonadismo é uma síndrome clínica e bioquímica que pode estar associada a um prejuízo significativo na qualidade de vida (QoL) do homem. Com o aumento na expectativa de vida e sobrevida do câncer prostático (CaP), espera-se um número maior de diagnósticos de hipogonadismo em homens submetidos ao tratamento potencialmente curativo do CaP. Apesar da contraindicação clássica do emprego de terapia de reposição com testosterona (TRT) em homens com diagnóstico ou suspeita de CaP, não há evidência convincente de que a normalização dos níveis de testosterona séricos em homens com baixos níveis seja deletéria. Em poucas séries de casos que descreveram a TRT após o tratamento do CaP, não houve casos de progressão clínica ou bioquímica do tumor. Não obstante a literatura seja limitada, os dados disponíveis sugerem que a TRT pode ser considerada em homens hipogonádicos selecionados, previamente tratados curativamente para o CaP de baixo risco e sem evidência de doença ativa.


Hypogonadism is a clinical and biochemical syndrome which may cause significant detriment in the quality of life. With the increase in life expectancy and prostate cancer survival a significant increase in the number of men with hypogonadism who have undergone presumably curative treatment for PCa is anticipated. Despite the widespread contraindication of testosterone in men with known or suspected prostate cancer, there is no convincing evidence that the normalization of testosterone serum levels in men with low, but not castrate levels, is deleterious. Although further studies are necessary before definitive conclusions can be drawn, the available evidence suggests that testosterone replacement therapy can be cautiously considered in selected hypogonadal men treated with curative intent for low risk prostate cancer and without evidence of active disease.


Subject(s)
Humans , Male , Androgens/therapeutic use , Carcinoma/therapy , Hormone Replacement Therapy , Hypogonadism/drug therapy , Prostatic Neoplasms/therapy , Testosterone/therapeutic use , Brachytherapy , Hormone Replacement Therapy/adverse effects , Prostatectomy , Time Factors , Testosterone/adverse effects
18.
Arq. bras. endocrinol. metab ; 53(8): 989-995, nov. 2009. tab
Article in English | LILACS | ID: lil-537036

ABSTRACT

OBJECTIVE: To compare the modalities of treatment for male hypogonadism available in Brazil. METHODS: Thirty-two men with late-onset hypogonadism ("andropause") were followed-up in the Hospital de Guarnição de Florianópolis, in Florianópolis, south Brazil. Clinical diagnosis was established according to AMS questionnaire (positive if equal to or higher than 27 points), and laboratorial diagnosis was made through low values of total testosterone (under 300 ng/dL) and/or free calculated testosterone (under 6.5 ng/dL). Patients were randomized to three non-enteral treatment groups (Deposteron® - 11 patients; Durateston® - 11 patients; and Nebido® - 10 patients). RESULTS: Clinically, Nebido® seemed to be superior when compared to Deposteron® (mean value of improvement percentage; p = 0.03) and when compared to Durateston® (post-treatment average AMS score; p = 0.03). According to laboratorial analysis, Nebido® showed higher testosterone levels than Deposteron® and Durateston® (p < 0.001). CONCLUSIONS: All non-enteral testosterone formulas available in the Brazilian market are efficient in raising testosterone levels and in clinical improvement of hypogonadal patients. Nebido® showed both a better clinical and laboratorial effectiveness.


OBJETIVO: Comparar os tratamentos para hipogonadismo masculino disponíveis no Brasil. MÉTODOS: Foram selecionados 32 homens com hipogonadismo tardio ("andropausa") no Hospital de Guarnição de Florianópolis. O diagnóstico foi feito por meio do questionário AMS (acima de 27 pontos) e dos níveis diminuídos de testosterona total dosada (abaixo de 300 ng/dL) e/ou testosterona livre calculada (abaixo de 6,5 ng/dL). Os pacientes foram divididos em três grupos de tratamento parenteral (Deposteron® - 11 pacientes; Durateston® - 11 pacientes; Nebido® - 10 pacientes). RESULTADOS: Clinicamente, o tratamento com Nebido® mostrou-se superior ao tratamento com Deposteron® (média do percentual de melhora; p = 0,03) e ao Durateston® (média do questionário AMS pós-tratamento; p = 0,03). Laboratorialmente, o tratamento com Nebido® mostrou níveis de testosterona superiores ao Deposteron® e Durateston® (p < 0,001). CONCLUSÕES: As três formulações de testosterona parenteral existentes no mercado brasileiro são eficientes em elevar os níveis de testosterona e melhorar clinicamente pacientes hipogonádicos, sendo o Nebido® mais efetivo clínica e laboratorialmente.


Subject(s)
Humans , Male , Middle Aged , Androgens/therapeutic use , Andropause/drug effects , Hypogonadism/drug therapy , Testosterone/analogs & derivatives , Analysis of Variance , Brazil , Hormone Replacement Therapy , Hypogonadism/blood , Injections, Intramuscular , Testosterone/adverse effects , Testosterone/therapeutic use
19.
Arq. bras. endocrinol. metab ; 53(8): 996-1004, nov. 2009. tab, graf
Article in English | LILACS | ID: lil-537037

ABSTRACT

OBJECTIVE: To assess the efficacy and safety of testosterone replacement in males with late-onset hypogonadism compared to hypogonadal men without replacement, and controls, during six months. METHODS: We assessed, through ADAM, AMS, IIEF-5 and SF-36 questionnaires, and through clinical and laboratorial examinations, 62 patients divided into three groups: 17 hypogonadal males (HR) used intramuscular testosterone every three weeks; 14 hypogonadal males (HV) and 31 non-hypogonadal males (CV) used oral vitamins daily. RESULTS: When compared to others, HR group obtained libido improvement assessed by ADAM 1 (p = 0.004), and borderline sexual potency improvement assessed by IIEF-5 (p = 0.053), besides a decrease in waist circumference after eight weeks (p = 0.018). The remaining parameters did not differ between the groups. PSA and hematocrit remained stable in those using testosterone. CONCLUSION: Six months of testosterone replacement improved sexuality and body composition, with prostatic and hematological safety.


OBJETIVO: Avaliar a eficácia e a segurança da reposição de testosterona em homens com hipogonadismo tardio comparados a hipogonádicos sem reposição e controles, durante seis meses. MÉTODOS: Mediante os questionários ADAM, AMS, IIEF-5 e SF-36, foram feitos exame clínico e laboratorial em 62 pacientes divididos em três grupos: 17 hipogonádicos (HR) usaram testosterona intramuscular a cada três semanas; 14 hipogonádicos (HV) e 31 não hipogonádicos (CV) usaram vitaminas via oral diariamente. RESULTADOS: Comparado aos demais, o grupo HR obteve melhora da libido avaliada pelo ADAM 1 (p = 0,004) e melhora limítrofe da potência sexual avaliada pelo IIEF-5 (p = 0.053), além de diminuição da cintura a partir da oitava semana (p = 0,018). Os demais parâmetros não foram diferentes entre os grupos. PSA e hematócrito se mantiveram estáveis nos que usaram testosterona. CONCLUSÃO: A reposição de testosterona durante seis meses melhorou a sexualidade e a composição corporal, com segurança prostática e hematológica.


Subject(s)
Aged , Humans , Male , Androgens/administration & dosage , Body Composition/drug effects , Hormone Replacement Therapy , Hypogonadism/drug therapy , Libido/drug effects , Testosterone/administration & dosage , Androgens/adverse effects , Epidemiologic Methods , Hormone Replacement Therapy/adverse effects , Hypogonadism/blood , Time Factors , Testosterone/adverse effects , Waist Circumference/drug effects
20.
J. bras. med ; 96(4): 11-15, abr. 2009. ilus
Article in Portuguese | LILACS | ID: lil-539057

ABSTRACT

As mulheres no climatério, principalmente na pós-menopausa, apresentam redução dos níveis de androgênio - sobretudo da testosterona livre - de aproximadamente 50 por cento, quando comparadas com as de 20 anos. Isso ocorre porque há um acréscimo da testosterona ligada à SHBG, o que a inativa, com a consequente perda da libido, do bem-estar e da energia. A terapia de reposição androgênica se mostra benéfica na medida em que melhora o desejo sexual, a depressão, o aumento de massa magra e o bem-estar. Entretanto, há efeitos colaterais que são correlacionados com as doses e a via de administração. As doses baixas, através das vias periféricas, minimizam acentuadamente esses efeitos. O presente estudo faz uma revisão na literatura das indicações e contraindicações dessa terapia, além de avaliar as formas de administração desses hormônios.


Subject(s)
Female , Adult , Middle Aged , Menopause , Menopause/physiology , Menopause/metabolism , Estrogen Replacement Therapy/adverse effects , Estrogen Replacement Therapy , Postmenopause , Quality of Life , Risk Factors , Testosterone/deficiency , Testosterone/adverse effects , Testosterone/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL